AGN 210676

AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.

Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor

Research Areas >> Inflammation/Immunology

EP2 Receptor:5 nM (EC50)

hEP3A Receptor:153 nM (EC50)

hDP Receptor:7749 nM (EC50)

AGN 210676 (Compound 23) also is a less potent agonist for recombinant human prostaglandin receptors hEP3A and hDP with EC50s of 153 nM and 7749 nM, respectively. AGN 210676 is useful for the treatment of glaucoma, ocular hypertension, inflammatory bowel disease, and the other diseases or conditions disclosed herein[1].

[1]. Old, David W, et al. SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS. US20070203222A1.

Dinoprostone | Prostaglandin E1 | E7046 | ONO-AE3-208 | PF 04418948 | Fevipiprant | grapiprant | TG6-10-1 | Taprenepag | GW 627368 | MRE-269 | Ramatroban | AH 6809 | Laropiprant | AZD1981